Navigation überspringen
Universitätsbibliothek Heidelberg
Verfasst von:Chia, Stephen K.
 Speers, Caroline H.
 D'yachkova, Yulia
 Kang, Anna
 Malfair‐Taylor, Suzanne
 Barnett, Jeff
 Coldman, Andy
 Gelmon, Karen A.
 O'Reilly, Susan E.
 Olivotto, Ivo A.
Titel:The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancer
Verlagsort:Hoboken
Verlag:Wiley Subscription Services, Inc., A Wiley Company
 Wiley-Liss
Jahr:2007
Umfang:7 S.
Fussnoten:Fax: (604) 877‐0585 ; ObjectType-Article-1 ; ObjectType-Feature-2 ; Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31 to June 3, 2003. ; SourceType-Scholarly Journals-1 ; content type line 23
Inhalt:BACKGROUND. Over the past decade, a number of new therapeutic agents have become available in the treatment of metastatic breast cancer (MBC). This study characterized the use and assessed the impact on survival of population‐based access to new agents for the treatment of MBC. METHODS. The dates of release in British Columbia of 7 new systemic agents for MBC during the 1990s were used to construct 4 time cohorts. All patients with a first diagnosis of distant metastases in each of the time cohorts were identified and characterized, and their survival was compared. Cox proportional regression modeling was used to assess for predictors of survival. RESULTS. In total, 2150 patients with a first distant metastases diagnosed during 1 of the 4 cohort intervals were identified. Baseline characteristics between cohorts were similar, except a greater proportion of the later cohorts received adjuvant chemotherapy (P < .001), had positive estrogen receptor status (P = .01), and had a longer median time from initial diagnosis to MBC (P < .001). Survival in Cohort 1 (1991–1992) and Cohort 2 (1994–1995; median, 438 days and 450 days, respectively) was similar. Survival was longer in Cohort 3 (1997–1998; median, 564 days; P = .002) and improved further in Cohort 4 (1999–2001; median, 667 days; P = .05). In multivariate analysis, the later cohorts were associated independently with improved survival (P = .01 and P < .001, respectively). CONCLUSIONS. Population‐based access to new therapeutic agents for MBC appeared to be associated with improved survival. To the authors' knowledge, this is the first study to date that demonstrates, from a population‐based perspective, improving survival over the past decade for women with MBC. Cancer 2007. © 2007 American Cancer Society. The results from this population‐based study demonstrated improved survival over time in a large cohort of women with metastatic breast cancer (MBC). Population‐based access to new therapeutic agents for MBC appeared to be associated with this improved survival.
ISSN:0008-543X
Titel Quelle:Cancer
Jahr Quelle:2007
Band/Heft Quelle:110, 5, S. 973-979
DOI:doi:10.1002/cncr.22867
URL:http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fonlinelibrary.wiley.com%2Fdoi%2Fabs%2F10.1002%2Fcncr.2286 ...
 http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F17647245
 http://www.ub.uni-heidelberg.de/cgi-bin/edok?dok=https%3A%2F%2Ffanyv88.com%3A443%2Fhttps%2Fsearch.proquest.com%2Fdocview%2F68292442
 DOI: https://doi.org/10.1002/cncr.22867
Sprache:English
Sach-SW:Adult
 Aged
 Antineoplastic Agents, Hormonal - therapeutic use
 Biological and medical sciences
 Breast Neoplasms - drug therapy
 Breast Neoplasms - epidemiology
 Breast Neoplasms - pathology
 British Columbia - epidemiology
 chemotherapy
 Cohort Studies
 Databases as Topic - statistics & numerical data
 Drug Therapy - methods
 Drug Therapy - statistics & numerical data
 Female
 Gynecology. Andrology. Obstetrics
 hormone therapy
 Humans
 Kaplan-Meier Estimate
 Mammary gland diseases
 Medical sciences
 metastatic breast cancer
 Middle Aged
 Multivariate Analysis
 Neoplasm Metastasis
 Prognosis
 Proportional Hazards Models
 survival
 Treatment Outcome
 Tumors
Verknüpfungen:→ Sammelwerk


zum Seitenanfang